hVIVO flags contract setback and record order book

hVIVO PLC (AIM:HVO) reported the cancellation and postponement of two trials due to pharmaceutical sector uncertainty and weak biotech funding in the US, but noted a record sales pipeline with large contracts in late-stage negotiations, including a potential Phase III human challenge trial. The company has secured £47 million in revenue for 2025 and anticipates a mid-single-digit operating loss if no further contracts are secured, though the risk of further cancellations is considered low. Integration of recent acquisitions is progressing well, and the company is targeting a more diversified revenue base.

Analysis

hVIVO PLC (AIM:HVO) has presented a mixed operational outlook, detailing the cancellation of one trial and the postponement of another, attributed to broader pharmaceutical sector uncertainty and constrained biotech funding, particularly in the United States. Despite this, the company has secured £47 million in revenue for 2025, which includes fees from the impacted studies, and assesses the risk of further cancellations for 2025 as low, given most trials are already active. Significantly, hVIVO reports a record sales pipeline, featuring several large contracts in late-stage negotiations, notably including a potential world's first Phase III human challenge trial (HCT), indicating robust underlying demand for its services. The company projects a mid-single-digit operating loss before exceptional items for 2025 should no additional contracts be secured; however, management remains confident in continued growth, supported by successful diversification efforts into hLAB services and early-phase clinical trial services via its well-integrating recent acquisitions, CRS Mannheim and Kiel. These new opportunities are anticipated to contribute materially to 2026 revenues, aligning with the moderately positive sentiment and optimistic tone indicated by market signals, which focus on future potential despite current disruptions.

Key Decisions for Investors

• Investors should weigh the near-term impact of trial disruptions and the stated risk of a mid-single-digit operating loss for 2025 if new contracts are not promptly secured, against the significant long-term potential presented by a record sales pipeline.
• Closely monitor announcements regarding the conversion of the substantial sales pipeline, particularly the large-value HCT contracts, as these are crucial for offsetting recent setbacks and confirming the company's growth trajectory beyond the already secured £47 million for 2025.
• The upcoming half-year trading update in July will be a key catalyst, providing critical insights into pipeline conversion rates, the financial contribution of recent acquisitions, and any revisions to the company's outlook; this update should be pivotal for assessing future performance.